Directorio de personas
Anabel Sorolla Bardaji

Anabel Sorolla Bardaji

Grado: Doctor/a


asorolla(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/E-2546-2012

Grupos

Publicaciones

  • Parisi E; Sorolla A; Montal R; González-Resina R; Novell A; Salud A; Sorolla MA

    Prognostic Factors Involved in the Epithelial-Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis.

    Cancers 12 1-28. .

    [doi:10.3390/cancers12113330]

  • Sorolla, A; Sorolla, MA; Wang, E; Ceña V

    Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment.

    Expert Opinion on Drug Delivery 17 1-17. .

    [doi:10.1080/17425247.2020.1814733]

  • Wang E; Sorolla A

    Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition.

    Journal of Gynecologic Oncology 31 -. .

    [doi:10.3802/jgo.2020.31.e29]

  • Wang, E; Sorolla, MA; Krishnan PDG; Sorolla, A

    From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.

    Biomolecules 10 -. .

    [doi:10.3390/biom10020248]

  • Sorolla A; Wang E; Golden E; Duffy C; Henriques ST; Redfern AD; Blancafort P

    Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics.

    ONCOGENE 39 1167-1184. .

    [doi:10.1038/s41388-019-1056-3]

  • Duffy C; Sorolla A; Wang E; Golden E; Woodward E; Davern K; Ho D; Johnstone E; Pfleger K; Redfern A; Iyer KS; Baer B; Blancafort P

    Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer.

    npj Precision Oncology 4 24-24. .

    [doi:10.1038/s41698-020-00129-0]

  • Kretzmann JA; Evans CW; Moses C; Sorolla A; Kretzmann AL; Wang E; Ho D; Hackett MJ; Dessauvagie BF; Smith NM; Redfern AD; Waryah C; Norret M; Iyer KS; Blancafort P

    Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers.

    Chemical Science 10 7718-7727. .

    [doi:10.1039/c9sc01432b]

  • Sorolla A; Wang E; Clemons TD; Evans CW; Plani-Lam JH; Golden E; Dessauvagie B; Redfern AD; Swaminathan-Iyer K; Blancafort P

    Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides.

    Nanomedicine-Nanotechnology Biology and Medicine 20 102003-102003. .

    [doi:10.1016/j.nano.2019.04.006]

  • Wang E; Sorolla A; Cunningham PT; Bogdawa HM; Beck S; Golden E; Dewhurst RE; Florez L; Cruickshank MN; Hoffmann K; Hopkins RM; Kim J; Woo AJ; Watt PM; Blancafort P

    Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.

    ONCOGENE 38 140-150. .

    [doi:10.1038/s41388-018-0421-y]

  • Clemons TD; Singh R; Sorolla A; Chaudhari N; Hubbard A; Iyer KS

    Distinction Between Active and Passive Targeting of Nanoparticles Dictate Their Overall Therapeutic Efficacy.

    LANGMUIR 34 15343-15349. .

    [doi:10.1021/acs.langmuir.8b02946]

  • Shrestha S; Sorolla A; Fromont J; Blancafort P; Flematti GR

    Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells.

    Marine Drugs 16 -. .

    [doi:10.3390/md16100361]

  • Shrestha S; Sorolla A; Fromont J; Blancafort P; Flematti GR

    Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells.

    Marine Drugs 16 -. .

    [doi:10.3390/md16020053]

Proyectos

  • DEVELOPMENT OF PRECISION THERAPIES FOR TRIPLE NEGATIVE BREAST CANCERS BASED ON CRISPR/CAS9 RIBONUCLEOPROTEINS.
  • Development of precision therapies for triple negative breast cancer based on CRISPR/Cas12a ribonucleoproteins
  • Contrato Miguel Servet - Proyecto + RRHH
  • EXPRESION DE CANALES DE CALCIO DE TIPO T EN NEOPLASIAS MELANOCÍTICAS BENIGNAS Y MALIGNAS. EVALUACION DE SU APLICICABILIDAD CLINICA COMO DIANAS TERAPEUTICAS EN EL MELANOMA